73 related articles for article (PubMed ID: 12243982)
1. Troxacitabine activity in extramedullary myeloid leukemia.
Alvarado Y; Kantarjian HM; Cortes JE; Apostolidou E; Bivins C; Giles FJ
Hematology; 2002 Jun; 7(3):179-85. PubMed ID: 12243982
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
[TBL] [Abstract][Full Text] [Related]
3. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Giles FJ; Cortes JE; Baker SD; Thomas DA; O'Brien S; Smith TL; Beran M; Bivins C; Jolivet J; Kantarjian HM
J Clin Oncol; 2001 Feb; 19(3):762-71. PubMed ID: 11157029
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
Giles FJ; Garcia-Manero G; Cortes JE; Baker SD; Miller CB; O'Brien SM; Thomas DA; Andreeff M; Bivins C; Jolivet J; Kantarjian HM
J Clin Oncol; 2002 Feb; 20(3):656-64. PubMed ID: 11821445
[TBL] [Abstract][Full Text] [Related]
5. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Giles FJ; Kantarjian HM; Cortes JE; Garcia-Manero G; Verstovsek S; Faderl S; Thomas DA; Ferrajoli A; O'Brien S; Wathen JK; Xiao LC; Berry DA; Estey EH
J Clin Oncol; 2003 May; 21(9):1722-7. PubMed ID: 12721247
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
Roboz GJ; Giles FJ; Ritchie EK; Allen-Bard S; Curcio TJ; Wilkes MA; Park SL; Kantarjian HM; Faderl S; Ravandi F; Kelner MJ; Feldman EJ
J Clin Oncol; 2007 Jan; 25(1):10-5. PubMed ID: 17146106
[TBL] [Abstract][Full Text] [Related]
7. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
[TBL] [Abstract][Full Text] [Related]
8. Troxacitabine-based therapy of refractory leukemia.
Giles FJ
Expert Rev Anticancer Ther; 2002 Jun; 2(3):261-6. PubMed ID: 12113049
[TBL] [Abstract][Full Text] [Related]
9. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
de Bono JS; Stephenson J; Baker SD; Hidalgo M; Patnaik A; Hammond LA; Weiss G; Goetz A; Siu L; Simmons C; Jolivet J; Rowinsky EK
J Clin Oncol; 2002 Jan; 20(1):96-109. PubMed ID: 11773159
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Lin CC; Beeram M; Rowinsky EK; Takimoto CH; Ng CM; Geyer CE; Denis LJ; De Bono JS; Hao D; Tolcher AW; Rha SY; Jolivet J; Patnaik A
Cancer Chemother Pharmacol; 2009 Dec; 65(1):167-75. PubMed ID: 19449006
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity.
Gourdeau H; Bibeau L; Ouellet F; Custeau D; Bernier L; Bowlin T
Cancer Chemother Pharmacol; 2001 Mar; 47(3):236-40. PubMed ID: 11320667
[TBL] [Abstract][Full Text] [Related]
12. A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
Vose JM; Panwalkar A; Belanger R; Coiffier B; Baccarani M; Gregory SA; Facon T; Fanin R; Caballero D; Ben-Yehuda D; Giles F
Leuk Lymphoma; 2007 Jan; 48(1):39-45. PubMed ID: 17325846
[TBL] [Abstract][Full Text] [Related]
13. Troxacitabine in leukemia.
Swords R; Apostolidou E; Giles F
Hematology; 2006 Oct; 11(5):321-9. PubMed ID: 17607581
[TBL] [Abstract][Full Text] [Related]
14. Troxacitabine in acute leukemia.
Swords R; Giles F
Hematology; 2007 Jun; 12(3):219-27. PubMed ID: 17558697
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
16. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
17. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
[TBL] [Abstract][Full Text] [Related]
18. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Lee CK; Rowinsky EK; Li J; Giles F; Moore MJ; Hidalgo M; Capparelli E; Jolivet J; Baker SD
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2158-65. PubMed ID: 16609029
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia.
Quintás-Cardama A; Cortes J
Expert Opin Investig Drugs; 2007 Apr; 16(4):547-57. PubMed ID: 17371201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
